Glenmark Life Sciences has recently rebranded its identity to Alivus Life Sciences, marking an exciting new chapter in its journey.

This is consequent to the acquisition by Nirma Ltd., a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals.

The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.

This rebranding to Alivus Life Sciences marks an important milestone in the company’s journey. It symbolizes our commitment to enhancing services for our customers, stakeholders, and employees. While the company’s name has changed, its dedication to quality and innovation remains steadfast.

Alivus Life Sciences is a developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.

The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW). The company’s 4 manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1,424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe).